<DOC>
	<DOCNO>NCT00680329</DOCNO>
	<brief_summary>The purpose study evaluate adherence DuoTrav® reinforce use Travalert™ Dosing Aid .</brief_summary>
	<brief_title>Glaucoma Adherence Study , Spain</brief_title>
	<detailed_description>This study conduct Spain . An identical study conduct France , UK , Italy , Netherlands Protocol ID EMD-07-01 . A combined enrollment number present .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Cloprostenol</mesh_term>
	<criteria>Inclusion : Provide inform consent . Able follow instruction willing able attend require study visit . Able read complete study questionnaire . Clinical diagnosis ocular hypertension , primary openangle , pigment dispersion exfoliation glaucoma least one eye . Intraocular pressure consider safe , eye , assure clinical stability vision optic nerve throughout trial . Currently treat DuoTrav alone , dose even least 30 day , Visit 1 . Best correct visual acuity 20/200 Snellen good eye . Intraocular pressure ≤ 30 mm Hg eye . Evidence cause investigator consider patient nonadherent , level , glaucoma medication . Agree adherence could improve intervention dose aid describe study . Other protocoldefined inclusion criterion may apply . Exclusion : Presence primary secondary glaucoma list inclusion criterion . Any abnormality prevent reliable applanation tonometry study eye ( ) . Any known opacity patient uncooperativeness restricts adequate examination ocular fundus anterior chamber study eye ( ) . Concurrent infectious/noninfectious conjunctivitis , keratitis uveitis either eye . Intraocular conventional surgery laser surgery study eye ( ) less three month prior Visit 1 . Risk visual field visual acuity worsen consequence participation trial , investigator 's best judgment . Progressive retinal optic nerve disease cause . Women childbearing potential use reliable mean birth control . Women pregnant lactating . A condition , opinion Principal Investigator , would interfere optimal participation study , would present special risk patient . Participation investigational study within 30 day prior Visit 1 . Known medical history allergy , sensitivity poor tolerance component preparation use trial deem clinically significant opinion Principal Investigator . Unwillingness risk possibility darken iris , eyelash change periocular pigmentation . History , risk uveitis cystoid macular edema ( CME ) . Any physical disability prevents accurate use Travalert™ dosing aid . Unable accurately instill travoprost/timolol fix combination evening . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Adherence</keyword>
	<keyword>Compliance</keyword>
	<keyword>Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
</DOC>